AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00866268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High pressure suction drainage
Description: In order to mask the type of intervention from the patient and the investigators, both drainage systems had two drain catheters. One catheter allowed the blood to flow from the wound to the bottle. The second catheter connected the bottle to the vacuum source. In the experimental arm the second catheter was open, while in the control group it was closed. So that the system used could not be distinguished, the connection of the second catheter to the bottle was covered with opaque adhesive tape.Drains were removed after bleeding had ceased.
Study NCT02243917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-5083
Study NCT01977339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome Bupivacaine
Description: 10 cc of 266 mg liposome bupivacaine with 10 cc of Normal Saline
Study NCT01977339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 cc of 0.25% bupivacaine
Study NCT01153841 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix™( GSK1024850A)
Description: Intramuscular, 3 doses
Study NCT01153841 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa™
Description: Intramuscular, 3 doses
Study NCT03282643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 MG
Description: Rivaroxaban pill 10mg qd, day1 and day2 after femoral venepuncture
Study NCT03150537 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluviral influenza vaccine
Description: Influenza vaccine (Fluviral) given via Med-Jet H4 or IM injection
Study NCT01525823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-754807 (IGR-IR/IR Inhibitor)
Description: Tablets, Oral, 100mg, Once daily, Days 1 - 5 and 15 - 17
Study NCT01525823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets, Oral, (1000mg on Days 3 - 9) and (2000mg on Days 10 - 17), Once daily
Study NCT04915638 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental intervention group with enriched cookies
Description: Enriched cookies containing a micronutrients formula (vitamins, minerals, antioxidants, and omega-3 fatty acids) each day (Monday to Friday).
Study NCT02613741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle-based physical activity
Description: Obese subjects will undergo a randomized physical activity-based weight reduction program (12 weeks). The lifestyle intervention will be determined based on an initial evaluation of each subjects' energy expenditure (by indirect calorimetry). Caloric intake will be set to elicit the loss of 1 to 1.5 lbs/week. The subjects and the family will meet with a dietitian once/week for 12 weeks. The intervention group will undergo an aerobic exercise program 3 times/week. The duration of exercise will be progressively increased from 20 to 45 minutes/session. The subjects will keep daily record of exercise activity and food intake. Interventions will be monitored during the subjects' weekly visit with the research group and they will be given counseling to stick to the intervention program.
Study NCT04561687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Montelukast and nasal budesonide
Study NCT03282643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 MG
Description: Rivaroxaban pill 10mg bid, day1 and day2 after femoral venepuncture
Study NCT03282643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-molecular-weight heparin
Description: 0.4 ml once daily, before femoral venepuncture(day1) and the following day (day 2)
Study NCT02093260 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: Flubio (Influenza HA) Vaccine~The vaccine will be given intramuscularly.
Study NCT00911560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH
Description: Pts receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8, 20, 32, \& 52. Minor schedule adjustments are permitted, as needed. Vaccines must occur a minimum of 6 days apart. Induction of antibody response against the target antigens will be assessed. A fixed dose of oral β-glucan (40 mg/kg/day) is started at week 6 or 7(to allow time for generation of antibodies), \& continued as approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination. Neutrophils will be tested for glucan effects on cytotoxicity. Antineuroblastoma activity will be monitored using standard radiographic \& bone marrow studies, as well as RT-PCR for measurement of minimal residual disease in blood \& bone marrow. Phase II treatment schema for patients in 1st CR/VGPR or >2nd CR/VGPR will be the same for the vaccine as in phase I except OPT-821 will be given at a fixed dose of 150 mcg/m2.
Study NCT00911560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oral β-glucan
Description: Phase II Patients will be randomized to starting oral β-glucan (40 mg/kg/day) in week 1 or in week 6.
Study NCT04352816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetocardiogram
Description: Magnetocardiography (MCG) is a non-invasive, non-contact body-surface method which uses magnetometers to measure and map the magnetic fields generated by the electrical activity within the heart. It offers a better spatial resolution than an ECG recording and opens the possibility of detecting conduction characteristics consistent with arrhythmogenesis.9-15 The application of MCG has been limited by feasibility as devices up to now have been based on superconducting quantum interference devices (SQUID) with supercooled sensors. These machines were often operated in a shielded environment, to decrease magnetic field interference (noise) from electrical devices and other sources of magnetic fields. This was a major limiting factor in deploying these devices in a working environment especially considering, that most hospital wards will have numerous devices that can interfere with the device.
Study NCT00256750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine (CsA)
Description: tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months (ST), 100-250 ng/mL, daily, 24 months (LT)
Study NCT00256750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept LI (less intensive)
Description: solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
Study NCT00256750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept MI (more intensive)
Description: solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
Study NCT04561687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine
Description: Azelastine and nasal budesonide
Study NCT04561687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: To all groups
Study NCT01153841 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa™
Description: Intramuscular, 3 doses
Study NCT01877824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast-track training
Study NCT01125878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01125878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Starch composite B
Description: fiber mixture
Study NCT01125878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Starch composite C
Description: fiber mixture
Study NCT01125878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Starch composite D
Description: fiber mixture
Study NCT00447967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 200 mg/m2 IV on Day 1 every 3 weeks for 6 cycles
Study NCT00447967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 80 mg/m2 IV on Day 2 every 3 weeks for 6 cycles
Study NCT00447967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 400 mg/m2 infused over 10 min IV and Fluorouracil600 mg/m2 infused over 22 hours IV, Day 1 and 2 (De Grammont regimen)every 2 weeks for 12 cycles
Study NCT00447967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 200 mg/m2 infused over 1 hour IV on day 1 and day 2 (De Grammont regimen) every 2 weeks for 12 cycles
Study NCT00447967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m2 as a 4 hour IV infusion, Day 1 every 4 weeks for 6 cycles
Study NCT03980392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidomain intervention program
Description: Multidomain intervention program for physical exercise, cognitive training, nutrition, vascular and metabolic risk controls, and motivation
Study NCT03924804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer's solution acetate
Description: Intravenous infusion of 2 ml/kg Ringer's solution acetate within 1 hour after induction.
Study NCT03924804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer's solution acetate
Description: Intravenous infusion of 8ml/kg Ringer's solution acetate within 1 hour after induction.
Study NCT03924804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer's solution acetate
Description: Intravenous infusion of 16ml/kg Ringer's solution acetate within 1 hour after induction.
Study NCT04561687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide
Description: To all groups
Study NCT04561687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo and nasal budesonide
Study NCT02121275 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound of the lungs
Description: Ultrasound examination of the lungs
Study NCT02121275 — intervention group
Intervention type: DEVICE
Intervention: Electric impedance tomography
Description: Electric impedance tomography (EIT) is a noninvasive tool based on the measurement of electrical impedance changes within the thorax and lung tissue during ventilation and depicts the regional changes in ventilation in real time. To use electric impedance tomography 16 electrodes are applied in a circular fashion around the patient's chest, typically at the level of the 7th intercostal space.
Study NCT04386174 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neurofeedback
Description: Information about activity in pain-related regions of the brain will be shown to participants to determine if receiving this information is helpful in learning different thinking strategies (such as shifting attention, imagery, mantra meditation, etc.) that may help people with SCI change their experience of neuropathic pain.
Study NCT04051463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Netarsudil Ophthalmic Solution
Description: Netarsudil eye drops instilled once daily
Study NCT04051463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops instilled once daily
Study NCT04405440 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavioral avoidance task
Description: Behavioral task able to measure avoidance actions, US-expectancy, and reward-related indexes in different learning times
Study NCT00508092 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthetic administration
Description: Pre incision skin infiltration with local anesthetic 0.5% bupivacaine by weight~OR~Pre incision skin infiltration and deeper field infiltration (deep to external oblique) with local anesthetic 0.5% bupivavcaine by weight
Study NCT04672135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REM0046127
Description: Oral solution: 100 mg/mL REM0046127
Study NCT04672135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution with 0 mg/mL REM0046127
Study NCT01335126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emulsion type artificial tear
Description: 2 types of artificial tears
Study NCT03785184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: tablet; oral
Study NCT03785184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: capsule; oral
Study NCT03785184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: tablet; oral
Study NCT01207817 — intervention group
Intervention type: OTHER
Intervention: Pupillometry
Description: Pupillometry readings will be taken at low, intermediate and high ambient light
Study NCT02031432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol
Description: Film-coated tablet; strengths: 200, 400, or 600 µg
Study NCT04197986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Participants randomly assigned to infigratinib will receive hard gelatin capsules for oral administration of infigratinib 125 mg once a day (administered as one 100-mg capsule and one 25-mg capsule) using a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.
Study NCT04197986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomly assigned to placebo will receive placebo matching in appearance the investigational product (infigratinib), which will be provided as hard gelatin capsules for oral use and will be administered once daily on a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.
Study NCT02960698 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IRM and comportemental tasks
Study NCT02960698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IRM and comportemental tasks
Study NCT00653913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCH 58235
Description: SCH 58235 10 mg (once daily)
Study NCT04707079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Eligible subjects will be given duvelisib orally at a dose of 25 mg BID during each 28-day treatment cycle, for up to 12 cycles.
Study NCT02575144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 500mg PO twice daily on days 1-28 for a 28-day cycle
Study NCT00653913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pitavastatin
Description: Pitavastatin 2 mg (once daily)
Study NCT02849249 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: allergovac polimerized (100/100)
Description: Patients will recieve a initiation phase plus a mantenaince phase for 3 months of an allergy vaccine.
Study NCT00475540 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: synthetic monofilament polypropylene mesh
Description: Vaginal prolapse repair with mesh
Study NCT03027843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone
Description: in GH group, patients have weekly injections of GH dose 14 iu, until the day of hCG.
Study NCT04257227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The rTMS intervention will be performed in a dedicated rTMS patient room on the PC unit, where the patient can remain in their bed seated upwards at a 45 degree angle, or seated in a chair.~The stimulation intensity for treatment will be determined by measuring the resting and active motor threshold (rMT and aMT) using single pulse TMS over the motor cortex using standard techniques as in previous trials. Investigators will use left-sided intermittent theta burst stimulation (iTBS). The trained team member will locate the left DLPFC using the BeamF3 technique. For the open-label dose-finding study, this region will be stimulated intermittently at 3 TMS pulses every 200 milliseconds for 2 seconds (i.e. 30 stimulations). This procedure is repeated every 10 seconds for a total duration of 3 minutes during which 600 total pulses are delivered. Participants will receive up to 8 3-minute sessions daily at 45 minute intervals for 5 days (consecutively or in a seven-day window if need be).
Study NCT03026049 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep venous stenting
Description: Deep venous stent
Study NCT01714011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Ziprasidone's activity is primarily due to the parent drug. The multiple-dose pharmacokinetics of ziprasidone are dose-proportional within the proposed clinical dose range, and ziprasidone accumulation is predictable with multiple dosing. Elimination of ziprasidone is mainly via hepatic metabolism with a mean terminal half-life of about 7 hours within the proposed clinical dose range.~Steady-state concentrations are achieved within one to three days of dosing. The mean apparent systemic clearance is 7.5 mL/min/kg. Ziprasidone is unlikely to interfere with the metabolism of drugs metabolized by cytochrome P450 enzymes. Ziprasidone is well absorbed after oral administration, reaching peak plasma concentrations in 6 to 8 hours.
Study NCT03240718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: CORE fractional CO2 laser treatment
Study NCT02575144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of >60 cc/min
Study NCT00532428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene
Description: 60 mg QD
Study NCT00532428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene
Description: 120 mg QD
Study NCT00532428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01352065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: tablet, 250 mg per day, twice per day, 8 weeks
Study NCT01352065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: tablet, 10 mg per day, single per day, 8 weeks
Study NCT01352065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, 10 mg per day, single per day, 8 weeks
Study NCT02575144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: 25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of >60 cc/min
Study NCT02575144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle
Study NCT01804036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: Week 1: 10 mg Zolpidem daily for 1 week, Week 2: 10 mg Zolpidem daily for one week, taken as needed, Week 3: 5 mg Zolpidem daily for 1 week, taken as needed.
Study NCT01804036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Bridging
Description: An awareness training program. One 2 hr class per week for 3 weeks - 2 hours per session
Study NCT01768468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAYLA tablet
Description: 1 tablet twice a day
Study NCT01768468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JOINS tablet
Description: 1 tablet at each time, 3 times a day
Study NCT04718324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-PROMS
Description: Participants randomised to the e-PROMS arm will receive a safe link to the e-PROMS and a unique identification number in the electronic form, so as to preserve anonymity. This is a one-time intervention
Study NCT04718324 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: p-PROMS
Description: Participants randomised to the p-PROMS arm will receive the PROMS and PREMS questionnaires and a unique identification number in paper form.
Study NCT04492878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IKERVIS®1mg/mL
Description: One drop of study medication once daily in each eye at bedtime during 90 days.
Study NCT02993458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DASH diet
Description: DASH style diet rich in fruits, vegetables, and low-fat dairy foods and low in saturated fat and total fat
Study NCT02993458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH diet
Description: DASH style diet rich in fruits, vegetables, and low-fat dairy foods and low in saturated fat and total fat
Study NCT02993458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Na diet
Description: Sodium intake of 1500 mg/d (65 mmol, or 0.75 mg/Kcal/d), representing the Adequate Intake recommended by the Institute of Medicine.
Study NCT02993458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Na diet
Description: Sodium intake of 1500 mg/d (65 mmol, or 0.75 mg/Kcal/d), representing the Adequate Intake recommended by the Institute of Medicine.
Study NCT02993458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Na diet
Description: Sodium intake of 3500 mg/d (152 mmol, or 1.73 mg/Kcal/d, representing the highest sodium intake used for adults in the DASH Sodium trial.